Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $12.2 million.

  • Anika Therapeutics' Cost of Revenue rose 2051.03% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.1 million, marking a year-over-year increase of 13460.32%. This contributed to the annual value of $43.9 million for FY2024, which is 1476.48% up from last year.
  • As of Q3 2025, Anika Therapeutics' Cost of Revenue stood at $12.2 million, which was up 2051.03% from $13.9 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cost of Revenue registered a high of $17.7 million during Q4 2021, and its lowest value of -$8.7 million during Q4 2023.
  • Its 5-year average for Cost of Revenue is $11.9 million, with a median of $13.9 million in 2025.
  • As far as peak fluctuations go, Anika Therapeutics' Cost of Revenue tumbled by 13710.07% in 2022, and later skyrocketed by 25539.67% in 2024.
  • Over the past 5 years, Anika Therapeutics' Cost of Revenue (Quarter) stood at $17.7 million in 2021, then plummeted by 137.1% to -$6.6 million in 2022, then plummeted by 32.15% to -$8.7 million in 2023, then skyrocketed by 255.4% to $13.5 million in 2024, then dropped by 9.22% to $12.2 million in 2025.
  • Its Cost of Revenue stands at $12.2 million for Q3 2025, versus $13.9 million for Q2 2025 and $11.5 million for Q1 2025.